statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial...

Fort Myers Mayor to Proclaim June as NeoGenomics Commitment to Cancer Month

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers Mayor, Kevin Anderson, will be dedicating June as NeoGenomics Commitment to Cancer Month...

NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS Hematopathology Services portfolio at the American Society of...

NeoGenomics Earnings Analysis: Q1 Recap

Where NeoGenomics Stands With Analysts

Latest Ratings for NEO
 DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022NeedhamMaintainsBuy Feb 2022Raymond JamesMaintainsOutperform
 View More Analyst Ratings for NEO...

NeoGenomics Reports First Quarter 2024 Results

NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31...

NeoGenomics Announces Senior Leadership Promotions

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted...

NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company...

NeoGenomics (NEO, $15.39) Stochastic Oscillator left the overbought zone on April 01, 2024

This is a signal that NEO's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Volume	833,547.00
52-Wk High	$21.22
52-Wk Low	$11.03

NEO Neogenomics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals